← back to search

Maria Rogdaki

King's College London · GB
Area of research
Psychiatry and Mental health · Cognitive Neuroscience
Research interest
Research interests include Schizophrenia research and treatment, Functional Brain Connectivity Studies, Congenital heart defects research, and Advanced MRI Techniques and Applications.
h-index
24
citations
2,653
works
81
NIH funding
primary concept
email

Recent publications

Duration of Untreated Psychosis and Outcomes in First-Episode Psychosis: Systematic Review and Meta-analysis of Early Detection and Intervention Strategies
Schizophrenia Bulletin 2024cited by 48position: middledoi
Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis
The Lancet Child & Adolescent Health 2024cited by 27position: firstdoi
Umbrella Review: Atlas of the Meta-Analytical Evidence of Early-Onset Psychosis
Journal of the American Academy of Child & Adolescent Psychiatry 2024cited by 24position: middledoi
CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings
BMC Psychiatry 2024cited by 7position: middledoi
Shared and separate patterns in brain morphometry across transdiagnostic dimensions
Nature Mental Health 2023cited by 24position: middledoi
Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study
The British Journal of Psychiatry 2022cited by 30position: middledoi
The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study
Translational Psychiatry 2021cited by 58position: middledoi
Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study
Molecular Psychiatry 2021cited by 31position: firstdoi
Automated Data Quality Control in FDOPA brain PET Imaging using Deep Learning
Computer Methods and Programs in Biomedicine 2021cited by 23position: middledoi
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
Nature Communications 2020cited by 234position: middledoi
Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis
Molecular Psychiatry 2020cited by 68position: firstdoi
In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
JAMA Psychiatry 2019cited by 70position: middledoi
Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications
Psychopharmacology 2019cited by 51position: middledoi
Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study
Molecular Psychiatry 2018cited by 182position: middledoi
The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study
The Lancet Psychiatry 2018cited by 115position: middledoi
The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study
Biological Psychiatry 2018cited by 72position: middledoi
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology
Journal of Psychopharmacology 2017cited by 345position: middledoi
A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia
JAMA Psychiatry 2017cited by 231position: middledoi
Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia
Acta Psychiatrica Scandinavica 2017cited by 103position: middledoi
Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans.
Translational Psychiatry 2017cited by 60position: middledoi
Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms
Journal of Psychopharmacology 2015cited by 61position: middledoi
Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset
The FASEB Journal 2012cited by 188position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Oliver Howes · King's College London19 papers (2015–2024)Robert A. McCutcheon · Oxford Health NHS Foundation Trust9 papers (2015–2024)Mattia Veronese · University of Padua8 papers (2017–2021)Sameer Jauhar · Imperial College London8 papers (2017–2022)Federico Turkheimer · King's College London7 papers (2017–2021)Alice Egerton · King's College London6 papers (2018–2024)Tiago Reis Marques · King's College London6 papers (2015–2022)Toby Pillinger · King's College London5 papers (2017–2024)Philip McGuire · McGill University5 papers (2017–2024)Sridhar Natesan · King's College London4 papers (2017–2021)Matthew M. Nour · King's College London4 papers (2017–2018)Shitij Kapur · University of Sheffield3 papers (2017–2018)Gonzalo Salazar de Pablo · Universidad Complutense de Madrid3 papers (2024–2024)Pamela Hathway · King's College London3 papers (2018–2019)James Stone · Brighton and Sussex Medical School3 papers (2018–2018)Katherine Beck · King's College London3 papers (2015–2022)Ilaria Bonoldi · King's College London3 papers (2017–2021)Enrico D’Ambrosio · University of Bari Aldo Moro3 papers (2017–2024)Faith Borgan · King's College London3 papers (2018–2022)Declan Murphy · King's College London2 papers (2017–2020)